Einzeltreffer — DigiBib

Background: Hyperglycemia is commonly seen in critically ill patients. This disorder was also seen in coronavirus disease 2019 (COVID-19) patients and was associated with a worse prognosis. The current study determined the prevalence, risk factors, and prognostic implications of hyperglycemia in COVID-19 patients.

Method: This was a retrospective observational study performed in an intensive care unit for COVID-19 patients. Electronic data of COVID-19 patients admitted to the intensive care unit from August 2nd to October 15th, 2021, were collected. Patients were divided into non-hyperglycemia, hyperglycemia in diabetic patients, and hyperglycemia in non-diabetic patients. Primary outcomes were 28-day and in-hospital mortalities. Multinomial logistic regression and multivariable Cox regression models were used to determine the risk factors for hyperglycemia and mortality, respectively.

Results: Hyperglycemia was documented in 65.6% of patients: diabetic patients (44.8%) and new-onset hyperglycemia (20.8%). In-hospital and 28-day mortality rates were 30.2% and 26.1%, respectively. Respiratory failure, corticosteroid therapy, and a higher level of procalcitonin were risk factors for hyperglycemia in diabetic patients, whereas cardiovascular diseases, respiratory failure, and higher aspartate aminotransferase/glutamate aminotransferase ratio were risk factors for hyperglycemia in non-diabetic patients. The risk of the 28-day mortality rate was highest in the new-onset hyperglycemia (hazard ratio [HR] 3.535, 95% confidence interval [CI] 1.338-9.338, p=0.011), which was higher than hyperglycemia in type 2 diabetes mellitus patients (HR 1.408, 95% CI 0.513-3.862, p=0.506).

Conclusion: Hyperglycemia was common in COVID-19 patients in the intensive care unit. Hyperglycemia reflected the disease severity but was also secondary to therapeutic intervention. New-onset hyperglycemia was associated with poorer outcomes than that in diabetic patients.

Competing Interests: The authors have declared that no competing interests exist.

Titel:	Hyperglycemia in Severe and Critical COVID-19 Patients: Risk Factors and Outcomes.
Autor/in / Beteiligte Person:	Le, VT ; Ha, QH ; Tran, MT ; Le, NT ; Le, MK
Link:	Zum Volltext
Zeitschrift:	Cureus, Jg. 14 (2022-08-02), Heft 8, S. e27611
Veröffentlichung:	Palo Alto, CA : Cureus, Inc., 2022
Medientyp:	academicJournal
ISSN:	2168-8184 (print)
DOI:	10.7759/cureus.27611
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Cureus] 2022 Aug 02; Vol. 14 (8), pp. e27611. <i>Date of Electronic Publication: </i>2022 Aug 02 (<i>Print Publication: </i>2022). References: JAMA. 2020 Apr 7;323(13):1239-1242. (PMID: 32091533) ; Medicine (Baltimore). 2015 Sep;94(36):e1525. (PMID: 26356728) ; Diabetes Obes Metab. 2020 Aug;22(8):1443-1454. (PMID: 32406594) ; Front Endocrinol (Lausanne). 2020 Oct 08;11:582936. (PMID: 33133024) ; PLoS One. 2018 Apr 6;13(4):e0194952. (PMID: 29624594) ; Front Med (Lausanne). 2019 Mar 27;6:54. (PMID: 30972338) ; J Diabetes Sci Technol. 2020 Jul;14(4):813-821. (PMID: 32389027) ; Int J Environ Res Public Health. 2018 May 15;15(5):. (PMID: 29762485) ; Acta Diabetol. 2010 Sep;47(3):193-9. (PMID: 19333547) ; Diabetes Care. 2021 Dec;44(12):2645-2655. (PMID: 34625431) ; Diabetes Metab. 2017 Feb;43(1):40-47. (PMID: 27663631) ; Intensive Care Med. 2014 Jul;40(7):973-80. (PMID: 24760120) ; N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013) ; J Clin Endocrinol Metab. 2011 Jun;96(6):1789-96. (PMID: 21411550) ; JAMA. 2020 May 26;323(20):2052-2059. (PMID: 32320003) ; Diabetes Care. 2003 Feb;26(2):510-3. (PMID: 12547890) ; J Allergy Clin Immunol. 2020 Jul;146(1):110-118. (PMID: 32294485) ; Diabetes Obes Metab. 2020 Oct;22(10):1897-1906. (PMID: 32469464) ; N Engl J Med. 2001 Nov 8;345(19):1359-67. (PMID: 11794168) ; Cell Metab. 2020 Sep 1;32(3):437-446.e5. (PMID: 32697943) ; N Engl J Med. 2020 Dec 3;383(23):2255-2273. (PMID: 33264547) ; J Diabetes. 2021 Mar;13(3):253-260. (PMID: 33216443) ; Diabet Med. 2006 Jun;23(6):623-8. (PMID: 16759303) ; J Diabetes Complications. 2020 Sep;34(9):107671. (PMID: 32651031) ; Diabetes Res Clin Pract. 2020 Oct;168:108374. (PMID: 32805345) ; Diabetes Res Clin Pract. 2013 Mar;99(3):277-80. (PMID: 23298665) ; N Engl J Med. 1999 Dec 16;341(25):1906-12. (PMID: 10601511) Contributed Indexing: Keywords: corticosteroid; covid-19; diabetes; hyperglycemia; intensive care Entry Date(s): Date Created: 20220811 Latest Revision: 20220813 Update Code: 20231215 PubMed Central ID: PMC9356651

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Hyperglycemia in Severe and Critical COVID-19 Patients: Risk Factors and Outcomes.